Indivior PLC

BATS-CHIXE:INDVL Stock Report

Market Cap: UK£1.1b

Indivior Valuation

Is INDVL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INDVL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INDVL (£8.31) is trading below our estimate of fair value (£181.45)

Significantly Below Fair Value: INDVL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INDVL?

Key metric: As INDVL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INDVL. This is calculated by dividing INDVL's market cap by their current revenue.
What is INDVL's PS Ratio?
PS Ratio1.1x
SalesUS$1.18b
Market CapUS$1.34b

Price to Sales Ratio vs Peers

How does INDVL's PS Ratio compare to its peers?

The above table shows the PS ratio for INDVL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.4x
HCM HUTCHMED (China)
5x18.0%UK£2.4b
DPH Dechra Pharmaceuticals
5.8x7.9%UK£4.4b
APH Alliance Pharma
1.3x5.2%UK£240.6m
HIK Hikma Pharmaceuticals
1.7x3.8%UK£4.2b
INDVL Indivior
1.1x5.5%UK£1.1b

Price-To-Sales vs Peers: INDVL is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (3.4x).

Price to Sales Ratio vs Industry

How does INDVL's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x5.9%US$56.33m
No more companies available in this PS range
No. of Companies6PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: INDVL is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is INDVL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INDVL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: INDVL is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INDVL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£8.31
UK£13.87
+67.1%
16.5%UK£18.17UK£11.57n/a5
Nov ’25UK£7.11
UK£13.87
+95.3%
16.5%UK£18.17UK£11.57n/a5
Oct ’25UK£7.29
UK£17.81
+144.5%
11.7%UK£20.96UK£14.65n/a5
Sep ’25UK£9.35
UK£18.92
+102.4%
18.0%UK£25.16UK£15.03n/a5
Aug ’25UK£10.64
UK£19.95
+87.6%
19.3%UK£24.97UK£14.92n/a5
Jul ’25UK£12.30
UK£24.40
+98.4%
2.6%UK£25.21UK£23.51n/a4
Jun ’25UK£14.48
UK£24.25
+67.5%
2.3%UK£25.01UK£23.51n/a4
May ’25UK£14.27
UK£24.78
+73.6%
1.1%UK£24.96UK£24.41n/a3
Apr ’25UK£17.10
UK£24.80
+45.0%
1.8%UK£25.23UK£24.17n/a3
Mar ’25UK£17.66
UK£23.83
+35.0%
6.8%UK£25.01UK£21.55n/a3
Feb ’25UK£13.50
UK£24.12
+78.7%
7.9%UK£25.94UK£21.49n/a3
Jan ’25UK£11.90
UK£24.27
+104.0%
7.9%UK£26.10UK£21.62n/a3
Dec ’24UK£13.02
UK£22.84
+75.5%
11.2%UK£26.14UK£19.39n/a4
Nov ’24UK£16.02
UK£24.55
+53.3%
11.0%UK£27.31UK£20.10UK£7.114
Oct ’24UK£17.97
UK£24.17
+34.5%
11.0%UK£26.97UK£19.30UK£7.295
Sep ’24UK£18.11
UK£24.17
+33.4%
11.0%UK£26.97UK£19.30UK£9.355
Aug ’24UK£17.84
UK£24.84
+39.3%
3.0%UK£25.71UK£23.64UK£10.644
Jul ’24UK£18.31
UK£23.82
+30.1%
3.9%UK£25.02UK£22.87UK£12.304
Jun ’24UK£14.52
UK£24.41
+68.1%
3.8%UK£25.51UK£23.31UK£14.484
May ’24UK£15.30
UK£23.60
+54.2%
6.9%UK£25.01UK£21.02UK£14.274
Apr ’24UK£13.83
UK£23.62
+70.8%
6.6%UK£24.95UK£21.14UK£17.104
Mar ’24UK£15.17
UK£23.62
+55.7%
6.6%UK£24.95UK£21.14UK£17.664
Feb ’24UK£18.98
UK£24.91
+31.3%
4.3%UK£25.78UK£23.14UK£13.504
Jan ’24UK£18.53
UK£22.02
+18.9%
5.5%UK£23.97UK£20.83UK£11.904
Dec ’23UK£17.18
UK£21.48
+25.0%
3.3%UK£22.30UK£20.56UK£13.024
Nov ’23UK£16.80
UK£22.04
+31.2%
2.9%UK£23.01UK£21.22UK£16.024

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$744.64

7D

-6.6%

1Y

-7.2%

Formycon

€821.0m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€46.50

7D

-1.0%

1Y

-24.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€61.75

7D

-5.2%

1Y

16.1%